CP-88Пептидомиметик CP-88
An experimental cyclic peptidomimetic. Mouse and laboratory studies examined its effects on hematopoiesis, the formation of blood cells.
What the studies found
Animal research · 2024
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Study of multiple preparations
- Intact-mouse spleen colony formation
- Control 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control.
- Stemokin in the same table
- 14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark.
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
Study notes · methods, sources and limitations
Participants or model Source-specific experimental population
Important limitations
- Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.
- No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.
International Journal of Molecular Sciences 25(24):13385 · Publication record
About CP-88
Names in this research collection
CP88
Research background
Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.
Conference sources and research collaborators ↗
- Compound class
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
See preparation-specific records; human benefit not established here
Study methods
Source-specific designs and limitations below
Independent replication
Related reports are not automatically independent evidence
Source access
Linked publications; access and review scope shown per record
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2013
Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Study notes and original source
Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Vladislav I. Deigin · EP2046778B1 · patent family 38996830
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Results and tables
Reported patent results
Reported findings
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
Population or model Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Protein-antigen response | A tested cyclic compound reportedly increased antibody titers by 74% | A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result |
| Oral activity comparison | Some cyclic analogues retained oral analgesic activity where comparator peptides did not | Different neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective |
Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
- Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2024
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
Study notes and original source
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Defined synthetic peptide / analogue
Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
Results and tables
Reported findings and study design
Population or model Source-specific experimental population
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Intact-mouse spleen colony formation | Control 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control. | |
| Stemokin in the same table | 14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark. |
No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Source-specific experimental population
- Source reviewed
- Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-11-06.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗